President Lee to meet with WHO chief to discuss cooperation in healthcare

The World Bio Summit 2026 is a biotechnology-focused international event hosted in partnership by the World Health Organization and Korea. It matters because it creates a setting for healthcare leaders to discuss research, innovation, and cooperation across borders. The article identifies the summit as the reason WHO Director-General Tedros Adhanom Ghebreyesus is visiting Seoul.

The summit runs from Wednesday to Thursday. During the visit, Tedros is also scheduled to meet President Lee Jae Myung at Cheong Wa Dae. Lee plans to present Korea’s initiatives involving artificial intelligence, including healthcare applications, and discuss ways to strengthen cooperation with the WHO.

The article does not explain the partnership’s precise purpose or list the summit’s full agenda. It does show that Korea and the WHO are using the event to connect biotechnology, AI, and international healthcare cooperation. That cooperation could help spread useful innovations beyond Korea.

President Lee Jae Myung is South Korea’s president and the host of the meeting at Cheong Wa Dae. Tedros Adhanom Ghebreyesus is the World Health Organization’s director-general, its senior leader. Their meeting matters because it places national healthcare innovation and international public-health cooperation at the same table.

Lee plans to introduce initiatives involving artificial intelligence, including healthcare projects, to Tedros. He also plans to stress the need for close cooperation with the WHO. Tedros’s presence connects the discussion to the organization’s international role and to the World Bio Summit 2026, which he is visiting Seoul to attend.

The meeting is therefore both diplomatic and practical. Lee is presenting Korea’s ideas, while Tedros represents the WHO’s global network. Together, they can discuss ways to spread healthcare innovations, establish global AI hubs, and nurture biotechnology workforces internationally. The article does not report the meeting’s eventual outcomes.

The World Health Organization is the United Nations agency that leads international cooperation on public health. It helps countries work together on disease prevention, health emergencies, medical guidance, and stronger health systems. The article presents the WHO as a partner that can help healthcare innovations reach people worldwide.

Its director-general, Tedros Adhanom Ghebreyesus, is visiting Seoul for the World Bio Summit 2026 and is scheduled to meet President Lee. Lee plans to introduce Korea’s AI initiatives, including healthcare projects, and emphasize close cooperation with the WHO. The proposed cooperation includes global AI hubs and stronger biotechnology workforces.

The meeting shows how the WHO can connect national ideas with international needs. It does not describe a specific WHO program or agreement resulting from the meeting. However, its global coordinating role could help countries share knowledge, develop useful tools, and expand access to healthcare advances when governments and institutions work together.

The WHO’s global reach is commonly measured through its 194 Member States. That means cooperation involving the organization can potentially connect with health authorities across 194 countries. The article itself does not state this number, so it should be treated as established background information rather than a figure from the report.

In the Seoul meeting, President Lee plans to call for cooperation that spreads healthcare innovations around the world. The ideas include global hubs for artificial intelligence and the nurturing of global biotechnology workforces. These mechanisms could give more countries access to expertise, tools, and trained professionals.

Potential reach is not the same as guaranteed benefit. Countries would still need suitable infrastructure, funding, skills, and policies to use new technologies effectively. The article reports plans and priorities, not a completed program. If the proposed cooperation becomes practical, all 194 WHO Member States could potentially benefit, though the scale and timing would depend on implementation.

President Lee’s proposals combine artificial intelligence with biotechnology and international cooperation. The article says he plans to introduce initiatives involving AI technology, including healthcare-related efforts. He also plans to highlight global AI hubs and the nurturing of global biotechnology workforces.

A global AI hub could serve as a place where researchers, health institutions, and technology experts develop and share useful tools. A trained biotechnology workforce could provide the scientists, engineers, and health professionals needed to create, test, and apply those tools. The article does not name specific AI systems, diseases, or training programs.

The proposals are aimed at spreading the benefits of healthcare innovation across the world. They remain initiatives and priorities discussed before the meeting, not completed projects. Their impact would depend on cooperation between Korea, the WHO, and other countries, as well as on investment, skills, safe data use, and the ability to turn research into practical care.

If healthcare AI tools and biotechnology expertise become more widely available, countries could potentially detect disease earlier, design treatments faster, and improve how care is delivered. Innovation hubs could connect researchers, hospitals, governments, and technology specialists. This matters because discoveries are more useful when they can move from laboratories into everyday healthcare.

For example, an AI hub might help teams build a system that analyzes medical information or supports research. Trained biotechnology workers could then test the system, study biological findings, and adapt tools to local needs. These are general possibilities; the article does not name a specific tool or medical result. Its concrete proposal is cooperation through global AI hubs and bio workforces.

The current reality is that Lee is calling for closer WHO cooperation, not announcing completed global systems. Wider benefits would require funding, training, reliable health services, and responsible oversight. If those foundations develop, innovation could reach more countries and reduce the gap between where healthcare advances are created and where they are used.

Artificial intelligence works by processing large amounts of information and identifying patterns that people might miss. In healthcare, that information can include medical records, images, test results, or biological measurements. AI may then help clinicians estimate risks, spot warning signs, or organize evidence for decisions. These are established uses of AI, not specific systems described in the article.

In biological research, AI can compare genetic or molecular information, predict how biological processes may behave, and help researchers identify promising targets for medicines. A diagnostic system might flag an unusual image for expert review. A research model might narrow thousands of possible compounds to those worth testing. Human experts must still validate results and monitor safety.

The article says Lee plans to introduce AI initiatives, including healthcare efforts, and promote global AI hubs. It does not state which medical data or research methods Korea is using. Wider cooperation could help share tools and skills, but privacy, data quality, fairness, and clinical testing remain essential before AI-supported findings guide patient care.